Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 22, 2024

Novel CD123-Targeting Antibody–Drug Conjugate Pivekimab Sunirine for Relapsed or Refractory AML

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Lancet Oncol 2024 Mar 01;25(3)388-399, NG Daver, P Montesinos, DJ DeAngelo, ES Wang, N Papadantonakis, E Todisco, KL Sweet, N Pemmaraju, AA Lane, L Torres-Miñana, JE Thompson, MY Konopleva, CM Sloss, K Watkins, G Bedse, Y Du, KE Malcolm, PA Zweidler-McKay, HM Kantarjian

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading